Carl Camras Translational Research Awards

This award for young investigators working in areas of translational research honors Dr. Carl Camras, who is highly respected for his work as a glaucoma specialist and a research scientist. He is most widely recognized for developing prostaglandin analogues for the treatment of elevated IOP in patients with glaucoma. During his distinguished career, he took a personal interest in developing the next generation of eye and vision researchers.

An award of $12,000 will be presented. This award, which was established in 2010, is supported through the ARVO Foundation.


Eligible nominees include young researchers who are 45 years of age or less at the time of nomination. Eligible nominees will have exhibited excellence in research and their fundamental scientific discoveries, concepts and novel technologies. Their discovery or observation must have led to, or have the promise of leading to, clinical application.

Other specific eligibility requirements for the nominee and the nominator include:

  • Neither nominees nor nominators are required to be ARVO members.
  • Foundation and ARVO Officers, Board members and Awards Committee members are not eligible to nominate or be nominated for an award during their terms, or to offer seconding letters of support.
  • Nominators and seconders may only support one nomination and should not be from the same institution as the nominee.
  • Previous recipients of the Carl Camras Translational Research Awards are not eligible.

Additional information:
  • Nominations may be resubmitted for a future year if unsuccessful.

Nomination process

Nominations are accepted via online application. The online nomination form requires the following information, forms and documents:

  • One letter of nomination from the nominator, describing in detail the contributions of the nominee and the impact of their translational research.

NOTE: Research that has possible translational implications at a later stage of development, such as snp polymorphisms associated with disease that have not yet lead to interventions, are not appropriate for this award.

  • Three supporting letters
  • A brief summary statement of nominee's significant achievements (maximum 75 words).
  • The nominee's five most significant articles must be referenced individually in the nomination form.
  • The nominee's current NIH biosketch or equivalent.
  • Indication of nominee's translational research having relatively immediate practicality for clinical care. Such support might consist of the following, but is not limited to these examples:
    • The research has led to an intervention-drug or device, for example- that is currently in Phase 1, 2 or 3 clinical trials
    • The research has led to a finding, like smoking and risk of AMD, that is now generally accepted and could result in preventive strategies.
    • The research provides strong, original evidence for change in clinical practice, such as overnight contact lens wear and risk of infection.
Review and selection process

Applications are reviewed by the ARVO Foundation Awards Committee comprised of internationally recognized experts. The deliberations of the Foundation Awards Committee are confidential and their decision is final.  


Applications open on Aug. 1

Applications close on Oct. 1

Recipients notified in Dec.

ARVO Foundation logo

2024 Recipient: Glenn Yiu, MD, PhD

Glenn Yiu is a retinal specialist and clinician-scientist working as a professor of ophthalmology at the University of California, Davis. He earned his dual MD-PhD degrees at Harvard Medical School, residency training at the Massachusetts Eye & Ear Infirmary, and vitreoretinal fellowship at Duke. He joined UC Davis in 2014, where he now leads a translational research program studying age-related macular degeneration (AMD) and other retinal diseases, with focus on ocular imaging technologies, gene editing and delivery, and animal models of retinal disease. Yiu reported the first use of CRISPR-based genome editing as a treatment strategy for wet AMD, discovered the use of microneedles for suprachoroidal gene delivery, and pioneered important studies on drusen evolution and other retinal disease models in rhesus monkeys. He also serves as director of tele-ophthalmology at UC Davis, where he has pioneered a teleretinal screening program to expand eye screening among diabetic patients in California. Yiu has received numerous awards including the Ronald G. Michels Fellowship, the Heed Fellowship, the Retina Society Fellowship Research Award, and the Macula Society Evangelos S. Gragoudas Award.